BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 15642428)

  • 1. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum.
    Gronlund B; Lundvall L; Christensen IJ; Knudsen JB; Høgdall C
    Eur J Surg Oncol; 2005 Feb; 31(1):67-73. PubMed ID: 15642428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
    Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A
    Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
    Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
    J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
    Yuan GW; Wu LY; Yao HW; Hou JL; Li XG; Liu LY
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
    Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
    Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multidisciplinary treatment of recurrent epithelial ovarian carcinoma and prognostic analysis].
    Huang X; Cai SM; Tang J; Li ZT; Zang RY
    Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):602-5. PubMed ID: 15498187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
    Eisenkop SM; Friedman RL; Wang HJ
    Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival?
    Eisenkop SM; Spirtos NM
    Gynecol Oncol; 2001 Sep; 82(3):435-41. PubMed ID: 11520137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
    Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
    Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma.
    Gadducci A; Viacava P; Cosio S; Fanelli G; Fanucchi A; Cecchetti D; Cristofani R; Genazzani AR
    Anticancer Res; 2003; 23(1B):549-56. PubMed ID: 12680144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
    Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A
    Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
    Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
    Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients.
    Zang RY; Yang WT; Shi DR; Xing Y; Cai SM
    J Surg Oncol; 2005 Jul; 91(1):67-72. PubMed ID: 15999350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
    Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
    Chi DS; McCaughty K; Diaz JP; Huh J; Schwabenbauer S; Hummer AJ; Venkatraman ES; Aghajanian C; Sonoda Y; Abu-Rustum NR; Barakat RR
    Cancer; 2006 May; 106(9):1933-9. PubMed ID: 16572412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
    Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
    Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.